Cite
HARVARD Citation
Emberley, E. et al. (n.d.). CB-839, a selective glutaminase inhibitor, has anti-tumor activity in renal cell carcinoma and synergizes with everolimus and receptor tyrosine kinase inhibitors. European journal of cancer. pp. S124-. [Online].